Effects of allergen-specific immunotherapy on peripheral blood regulatory T cells and serum concentrations of cytokines and immunoglobulins in horses with allergic dermatitis.

Abstract

The aim of this study was to assess the effect of allergen-specific immunotherapy (ASIT) on the immunological responses of horses. Blood samples were taken from thirty-two horses with allergic dermatitis treated with ASIT and 10 healthy control horses at 0, 3, 6, 9 and 12&#x202f;months to investigate the evolution of the percentage of regulatory T cells (Treg) in the peripheral blood and the serum levels of cytokines and immunoglobulins. Clinical improvement was appreciated by the majority of the horses' owners (56.6%). No effect of ASIT on CD4CD25Treg cells was found during the one year treatment period. No differences in the percentage of CD4T cells were observed between the groups, and no effects of ASIT over time were observed. The percentage of CD25T cells was always higher in the ASIT group (17.9&#x202f;&#xb1;&#x202f;11.3%) than in the control group (7.3&#x202f;&#xb1;&#x202f;4.4%, p&#x202f;<&#x202f;0.001). We did not detect any effect of ASIT on the serum levels of TGF-&#x3b2;, IL-10 and IFN-&#x3b3; or on the serum concentrations of IgA and IgG4. A reduction in the serum levels of total IgE in the horses with allergic dermatitis was observed at the 6th month (p&#x202f;<&#x202f;0.05), but increased again at the end of the study. The results indicate that immunotherapy was insufficient to induce significant changes that could indicate T cell tolerance, a shift in cytokine production to more protective Th1 cells. More studies are needed with new vaccine compositions and administration protocols to improve the immunological responses of the horses with allergic dermatitis.